These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 21947519)
1. Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice. El-Agamy DS; Shebl AM; Said SA Inflammopharmacology; 2011 Dec; 19(6):307-16. PubMed ID: 21947519 [TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological effects of Schistosoma mansoni infection associated with simultaneous exposure to malathion in Swiss outbred albino mice. Elsheikha HM; Hussein HS; Rahbar MH Acta Trop; 2008 Oct; 108(1):11-9. PubMed ID: 18722991 [TBL] [Abstract][Full Text] [Related]
3. Tranilast ameliorates impaired hepatic functions in Schistosoma mansoni-infected mice. Said E; Said SA; Elkashef WF; Gameil NM; Ammar EM Inflammopharmacology; 2012 Apr; 20(2):77-87. PubMed ID: 22278738 [TBL] [Abstract][Full Text] [Related]
4. Single-sex infection with female Schistosoma mansoni cercariae mitigates hepatic fibrosis after secondary infection. Koslowski N; Sombetzki M; Loebermann M; Engelmann R; Grabow N; Österreicher CH; Trauner M; Mueller-Hilke B; Reisinger EC PLoS Negl Trop Dis; 2017 May; 11(5):e0005595. PubMed ID: 28542175 [TBL] [Abstract][Full Text] [Related]
5. Anti-fibrotic Effect of Oral Versus Intraperitoneal Administration of Gold Nanoparticles in Hepatic Schistosoma mansoni-Infected Mice. Ahmed SAA; Gad SEM; Eida OM; Makhlouf LM Acta Parasitol; 2024 Mar; 69(1):190-202. PubMed ID: 37964174 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of Schistosoma mansoni infection in outbred albino mice exposed to Larvin contaminant. Attallah AM; Wahba MA; Elsheikha HM; Abbas AT; Abdel Aziz MM; El-Hemaly MA Parasitol Res; 2008 Aug; 103(3):567-76. PubMed ID: 18512077 [TBL] [Abstract][Full Text] [Related]
7. Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis. Elhenawy AA; Ashour RH; Nabih N; Shalaby NM; Megahed N Parasitol Int; 2017 Oct; 66(5):545-554. PubMed ID: 28408356 [TBL] [Abstract][Full Text] [Related]
8. Sodium valproate, a histone deacetylase inhibitor, with praziquantel ameliorates Schistosoma mansoni-induced liver fibrosis in mice. Elsakkar MG; Eissa MM; Hewedy WA; Nassra RM; Elatrebi SF Life Sci; 2016 Oct; 162():95-101. PubMed ID: 27528511 [TBL] [Abstract][Full Text] [Related]
9. The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis. Chatterjee S; Vrolix G; Depoortere I; Peeters T; Van Marck E BMC Infect Dis; 2005 Jun; 5():45. PubMed ID: 15949036 [TBL] [Abstract][Full Text] [Related]
10. Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis. Shaker ME; Shiha GE; Ibrahim TM Eur J Pharmacol; 2011 Nov; 670(2-3):593-600. PubMed ID: 21925495 [TBL] [Abstract][Full Text] [Related]
11. Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni. El-Lakkany NM; El-Maadawy W; Ain-Shoka A; Badawy A; Hammam O; Ebeid F Clin Exp Pharmacol Physiol; 2011 Oct; 38(10):695-704. PubMed ID: 21762203 [TBL] [Abstract][Full Text] [Related]
13. Ameliorative effect of bone marrow-derived stem cells on injured liver of mice infected with Schistosoma mansoni. El-Mahdi MM; Mansour WA; Hammam O; Mehana NA; Hussein TM Korean J Parasitol; 2014 Apr; 52(2):151-62. PubMed ID: 24850958 [TBL] [Abstract][Full Text] [Related]
14. Resveratrol protects against Schistosoma mansoni-induced liver fibrosis by targeting the Sirt-1/NF-κB axis. Mostafa DK; Eissa MM; Ghareeb DA; Abdulmalek S; Hewedy WA Inflammopharmacology; 2024 Feb; 32(1):763-775. PubMed ID: 38041753 [TBL] [Abstract][Full Text] [Related]
15. Improvement of the liver pathology by the aqueous extract and the n-butanol fraction of Sida pilosa Retz in Schistosoma mansoni-infected mice. Jatsa HB; Russo RC; Pereira CA; Aguilar EC; Garcia CC; Araújo ES; Oliveira JL; Rodrigues VF; de Oliveira VG; Alvarez-Leite JI; Braga FC; Louis-Albert Tchuem Tchuente ; Kamtchouing P; Negrão-Corrêa DA; Teixeira MM J Ethnopharmacol; 2016 Mar; 180():114-23. PubMed ID: 26806570 [TBL] [Abstract][Full Text] [Related]
16. Preventive CTLA-4-Ig Treatment Reduces Hepatic Egg Load and Hepatic Fibrosis in Sombetzki M; Rabes A; Bischofsberger M; Winkelmann F; Koslowski N; Schulz C; Reisinger EC Biomed Res Int; 2019; 2019():1704238. PubMed ID: 31950032 [TBL] [Abstract][Full Text] [Related]
17. Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection. Sobhy MMK; Mahmoud SS; El-Sayed SH; Rizk EMA; Raafat A; Negm MSI Exp Parasitol; 2018 Feb; 185():115-123. PubMed ID: 29331278 [TBL] [Abstract][Full Text] [Related]
18. The hepatoprotective activity of blue green algae in Schistosoma mansoni infected mice. Mohamed AH; Osman GY; Salem TA; Elmalawany AM Exp Parasitol; 2014 Oct; 145():7-13. PubMed ID: 25016189 [TBL] [Abstract][Full Text] [Related]
19. Imatinib activity on Schistosoma mansoni. Katz N; Couto FF; Araújo N Mem Inst Oswaldo Cruz; 2013 Nov; 108(7):850-3. PubMed ID: 24037106 [TBL] [Abstract][Full Text] [Related]
20. Antifibrotic and anthelminthic effect of casticin on Schistosoma mansoni-infected BALB/c mice. Lam HYP; Liang TR; Lan YC; Chang KC; Cheng PC; Peng SY J Microbiol Immunol Infect; 2022 Apr; 55(2):314-322. PubMed ID: 34167886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]